Affiliation:
1. Department of Respiratory and Critical Care Medicine Maoming People's Hospital Maoming China
2. Department of Otolaryngology Maoming People's Hospital Maoming China
3. Division of Pulmonary, Critical Care and Sleep Medicine Marshall University Huntington West Virginia USA
4. City Hospital Shahjahanpur India
5. Department of Respiratory Medicine Xinyi Second People's Hospital Maoming China
Abstract
AbstractIntroductionPatients presenting with brain metastases (BMs) from lung squamous cell carcinoma (LUSC) often encounter an extremely poor prognosis. A well‐developed prognostic model would assist physicians in patient counseling and therapeutic decision‐making.MethodsPatients with LUSC who were diagnosed with BMs between 2000 and 2018 were reviewed in the Surveillance, Epidemiology, and End Results (SEER) database. Using the multivariate Cox regression approach, significant prognostic factors were identified and integrated. Bootstrap resampling was used to internally validate the model. An evaluation of the performance of the model was conducted by analyzing the area under the curve (AUC) and calibration curve.ResultsA total of 1812 eligible patients' clinical data was retrieved from the database. Patients' overall survival (OS) was significantly prognosticated by five clinical parameters. The nomogram achieved satisfactory discrimination capacity, with 3‐, 6‐, and 9‐month AUC values of 0.803, 0.779, and 0.760 in the training cohort and 0.796, 0.769, and 0.743 in the validation cohort. As measured by survival rate probabilities, the calibration curve agreed well with actual observations. There was also a substantial difference in survival curves between the different prognostic groups stratified by prognostic scores. For ease of access, the model was deployed on a web‐based server.ConclusionsIn this study, a nomogram and a web‐based predictor were developed to assist physicians with personalized clinical decisions and treatment of patients who presented with BMs from LUSC.
Subject
Genetics (clinical),Pulmonary and Respiratory Medicine,Immunology and Allergy
Reference22 articles.
1. Cancer incidence, mortality, years of life lost, years lived with disability, and disability‐adjusted life years for 29 cancer groups from 2010 to 2019: a systematic analysis for the global burden of disease study 2019;Global Burden of Disease 2019 Cancer Collaboration;JAMA Oncol,2022
2. Epidemiology of Lung Cancer
3. Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献